NCT04099277
|
DNAM-1
|
LY3435151
|
2
|
aI/b1
|
Solid Tumor, Triple-negative Breast Cancer, Gastric Adenocarcinoma, Head and Neck Squamous Cell Carcinoma, Cervical Carcinoma, High Grade Serous Ovarian Carcinoma, Undifferentiated Pleomorphic Sarcoma, Leiomyosarcoma
|
Terminated
|
May 5, 2020
|
NCT04656535
|
TIGIT
|
AB154
|
46
|
0/I
|
Glioblastoma
|
Not yet recruiting
|
Jul, 2023
|
NCT03628677
|
TIGIT
|
AB154
|
66
|
I
|
Solid Tumor, Unspecified, Adult
|
Recruiting
|
Nov 10, 2021
|
NCT04262856
|
TIGIT
|
AB154
|
150
|
II
|
Non Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer, Squamous Non Small Cell Lung Cancer, Lung Cance
|
Recruiting
|
Jun 23, 2022
|
NCT04736173
|
TIGIT
|
AB154
|
625
|
III
|
Non Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer, Squamous Non-small-cell Lung Cancer, Lung Cancer
|
Recruiting
|
Jun 30, 2026
|
NCT03945253
|
TIGIT
|
ASP8374
|
6
|
I
|
Advanced Solid Tumors
|
Completed
|
Jun 12, 2020
|
NCT03260322
|
TIGIT
|
ASP8374
|
169
|
I
|
Advanced Solid Tumors
|
Active, not recruiting
|
Mar, 2022
|
NCT04693234
|
TIGIT
|
BGB-A1217
|
167
|
II
|
Cervical Cancer
|
Not yet recruiting
|
Mar 31, 2023
|
NCT04732494
|
TIGIT
|
BGB-A1217
|
280
|
II
|
Esophageal Squamous Cell Carcinoma
|
Recruiting
|
Mar, 2024
|
NCT04047862
|
TIGIT
|
BGB-A1217
|
234
|
I
|
Locally Advanced, Metastatic Solid Tumors
|
Recruiting
|
Aug, 2023
|
NCT04746924
|
TIGIT
|
BGB-A1217
|
605
|
III
|
Non-small Cell Lung Cancer
|
Not yet recruiting
|
Mar, 2025
|
NCT04150965
|
TIGIT
|
BMS-986207
|
104
|
I/II
|
Multiple Myeloma, Relapsed Refractory Multiple Myeloma
|
Recruiting
|
Mar 30, 2022
|
NCT04354246
|
TIGIT
|
COM902
|
45
|
I
|
Advanced Cancer, Ovarian Cancer; Lung Cancer, Colon Cancer; Plasma Cell Neoplasm, Breast Cancer
|
Recruiting
|
Sep 30, 2022
|
NCT04353830
|
TIGIT
|
IBI939
|
270
|
Ia/Ib
|
Advanced Malignancies
|
Recruiting
|
Dec 31, 2023
|
NCT04672369
|
TIGIT
|
IBI939
|
36
|
I
|
Advanced Lung Cancer
|
Not yet recruiting
|
Oct 9, 2024
|
NCT04672356
|
TIGIT
|
IBI939
|
20
|
I
|
Advanced Lung Cancer
|
Recruiting
|
Nov 9, 2024
|
NCT04457778
|
TIGIT
|
M6223
|
35
|
I
|
Metastatic Solid Tumors
|
Recruiting
|
Sep 14, 2022
|
NCT04305054
|
TIGIT
|
MK-7684
|
315
|
I/II
|
Melanoma
|
Recruiting
|
Apr 3, 2030
|
NCT04305041
|
TIGIT
|
MK-7684
|
200
|
I/II
|
Melanoma
|
Recruiting
|
Apr 3, 2030
|
NCT04303169
|
TIGIT
|
MK-7684
|
65
|
I/II
|
Melanoma
|
Recruiting
|
Apr 3, 2030
|
NCT04761198
|
TIGIT
|
MPH313
|
125
|
I/II
|
Solid Tumor, Adult Advanced Solid Tumor, Metastatic Solid Tumor
|
Recruiting
|
Jun 30, 2023
|
NCT04543617
|
TIGIT
|
MTIG7192A
|
750
|
III
|
Esophageal Squamous Cell Carcinoma
|
Recruiting
|
Dec 26, 2025
|
NCT04256421
|
TIGIT
|
MTIG7192A
|
470
|
III
|
Small Cell Lung Cancer
|
Recruiting
|
Sep 29, 2023
|
NCT04294810
|
TIGIT
|
MTIG7192A
|
560
|
III
|
Non-Small Cell Lung Cancer
|
Recruiting
|
Feb 21, 2025
|
NCT03708224
|
TIGIT
|
MTIG7192A
|
55
|
II
|
Cancer, Carcinoma, Squamous Cell Carcinoma, Head and Neck Cancer
|
Recruiting
|
Nov 30, 2025
|
NCT03563716
|
TIGIT
|
MTIG7192A
|
135
|
II
|
Non-small Cell Lung Cancer
|
Active, not recruiting
|
Oct 30, 2021
|
NCT03281369
|
TIGIT
|
MTIG7192A
|
410
|
I/II
|
Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma
|
Recruiting
|
Feb 11, 2023
|
NCT03119428
|
TIGIT
|
OMP-31 M32
|
33
|
I
|
Locally Advanced Cancer, Metastatic Cancer
|
Terminated
|
May 15, 2019
|
NCT04254107
|
TIGIT
|
SGN-TGT
|
231
|
I
|
Non-small Cell Lung Cancer, Gastric Carcinoma, Gastroesophageal Junction Carcinoma, Classical Hodgkin Lymphoma, Diffuse Large B-cell Lymphoma, Peripheral T-cell Lymphoma, Cutaneous Melanoma, Head and Neck Squamous Cell Carcinoma; Bladder Cancer, Ovarian Cancer, Triple Negative Breast Cancer
|
Recruiting
|
Mar 31, 2023
|
NCT04570839
|
CD112R
|
COM701
|
100
|
I/II
|
Endometrial Neoplasms, Ovarian Cancer, solid Tumor
|
Recruiting
|
Dec, 2023
|
NCT03667716
|
CD112R
|
COM701
|
140
|
I
|
Advanced Cancer, Ovarian Cancer, Breast Cancer, Lung Cancer, Endometrial Cancer, Ovarian Neoplasm, Triple Negative Breast Cancer, Lung Neoplasm, Neoplasm Malignant, Colo-rectal Cancer
|
Recruiting
|
Dec, 2021
|